Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-Escin
- Development stage
- Unknown
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Topical, Intravenous, Rectal
01
Overview
beta-Escin is an oleanane-type pentacyclic triterpenoid saponin extracted from the seeds of horse chestnut (Aesculus hippocastanum). It is primarily used as an anti-inflammatory and vasoconstrictive agent, indicated for the treatment of minor muscle and joint trauma, chronic venous insufficiency, hemorrhoids, inflammation, and edema. Its pharmacological effects include anti-edematous, anti-inflammatory, venotonic, antitumor, and antiviral activities. Mechanistically, beta-Escin inhibits Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) activation in endothelial cells under inflammatory conditions—leading to reduced migration and permeability—and modulates several signaling pathways such as ATM/H2AX, RhoA/Rock, GSK3/beta-catenin, HER2/HER3/Akt and PI3K/Akt. It also downregulates Lysyl oxidase homolog 2 (LOXL2) expression (implicated in cancer metastasis) and inhibits Pancreatic lipase. The compound has been shown to protect endothelial integrity against TNF-alpha-induced permeability changes[1][5][6][7][8].
- Other names
- escin iaisoescin iasodium aescinate
02
Targets
LOXL2 (Lysyl oxidase-like 2 protein)PNLIP (Pancreatic triacylglycerol lipase)
Beyond the preview
Go deeper on beta-Escin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta-Escin.